BMRN Related Earnings News
-
Deutsche Bank Upgrades BioMarin Pharma (BMRN) to Buy
-
BioMarin (BMRN) Decline Relates to High Expectations; Deutsche Bank Maintains Hold
-
Leerink Swann Says BioMarin (BMRN) BMN-673 Shows Promising Responses
-
BioMarin Pharmaceuticals, Inc. (BMRN) Misses Q1 EPS by 2c
-
BioMarin's BMN-701 has 60% Probability of Success, Says Analyst
-
BioMarin Pharmaceuticals, Inc. (BMRN) Posts Q4 GAAP Loss of 43c/Share; Guides FY13
-
Catyalyst (CPRX) Updates on Pipeline; Sees Filling NDA for Firdapse After Q115
-
Baird Expects Q413 Launch of BioMarin's (BMRN) GALNS
-
BioMarin Pharmaceuticals, Inc. (BMRN) Tops Q3 EPS by 16c
-
Jefferies Says GALNS to drive 30% Upside in BioMarin (BMRN)
-
BioMarin Pharma (BMRN) Sees FY12 Sales of About $500M, vs. $496M Consensus
-
Canaccord Genuity on BioMarin (BMRN): November Data + M&A Speculation = Top Pick
-
BioMarin Pharmaceuticals, Inc. (BMRN) Misses Q2 EPS by 6c
-
Canaccord Genuity Reiterates a 'Buy' on BioMarin Pharmaceutical (BMRN); Watching The Pipeline
-
BioMarin Pharma (BMRN) Misses Q1 EPS by 7c; Raises FY12 Sales Guidance
-
Canaccord Genuity on Biotechnology: Q1 Earnings Preview - What To Expect
-
Brean Murray Carret & Co. Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Buy; Increased Confidence in GALNS Phase 3 Trial
-
Baird Reiterates an 'Outperform' BioMarin Pharmaceutical (BMRN); Misses, Guides Lower, but Pipeline Events Remain Key
-
BioMarin Pharmaceuticals (BMRN) Misses Q4 EPS by 12c; Guides FY12 Revs Below
-
BioMarin Pharmaceuticals, Inc. (BMRN) Tops Q3 EPS by 14c
-
BioMarin Pharmaceuticals, Inc. (BMRN) Tops Q2 EPS by 6c; Guides FY11
-
BioMarin Pharmaceutical Inc. (BMRN) Reports Q1 Loss of $0.04
-
BioMarin Pharma (BMRN) Reports Q4 Adj-EPS of 10c; Guides FY11 Sales
-
Biomarin Pharma (BMRN) Tops Q3 EPS by 7c; Tightens FY10 Guidance
-
Biomarin (BMRN) Reports Mixed Q2 Results; Cuts FY10 Outlook
-
Biomarin Pharm (BMRN) Tops Q1 EPS by 8c; Guides In-line for FY Revenues
-
BioMarin Pharmaceutical (BMRN) Tops Q3 EPS by 12c; Guides
-
BioMarin Pharmaceutical (BMRN) Tops Q3 EPS by 12c; Guides
-
BioMarin Pharmaceutical (BMRN) Tops Q2 EPS By 10c; Raises Low-End of FY Revenue Guidance
-
BioMarin Pharmaceutical (BMRN) Tops Q1 EPS By 3c; Guides In-line for FY Revenues
-
BioMarin (BMRN) Reports Mixed Q4 Earnings; Guides FY09 Sales
-
BioMarin Pharmaceutical (BMRN) Reports Mixed Q2 Earnings; Guides FY08
-
BioMarin Pharmaceutical (BMRN) Tops Q1 EPS by 11c, Guides Higher for FY Revs
-
BioMarin Pharmaceutical (BMRN) Reports In-Line Q4 Earnings; Guides FY08 Revs
-
Biomarin Pharm (BMRN) Reports Q3 Loss of ($0.05)
-
BioMarin Pharmaceutical (BMRN) Reports Q2 Loss of $0.04
-
BioMarin (BMRN) Tops Q2 Views; Guides
-
BioMarin Pharmaceutical (BMRN) option implied volatility near average into EPS
-
BioMarin Pharmaceutical (BMRN) Tops Q1 EPS by 8c
-
BMRN Tops Q4 Views By 2c
-
BioMarin Pharmaceutical Reports A Q4 Loss
Back to BMRN Stock Lookup
